A potential coronavirus vaccine trial is entering human testing trials, according to Fox News.
Roughly 40 healthy people will participate in the trial's initial phase in Kansas City and at the University of Pennsylvania. Results should be ready by the summer.
"We immediately started testing the vaccine in the laboratory. And we're quite confident about the results that we've seen," Dr. Kate Broderick, senior vice president of research and development at Inovio Pharmaceuticals, told Fox News.
"We treated three people last week. But getting our vaccine into human beings is a huge step. But we did that in 83 days, which certainly in my career is absolutely an unprecedented level of speed."
Inovio began developing the vaccine once China shared the genome sequencing for coronavirus in January.
"In some patients, it looks like people who had the disease but now recovered have kind of these sort of low antibodies levels, but we don't know if that's a consistent result across everybody that's contracted the virus so far," she says.
"So, we need to learn more about how the virus affects people and how people are affected by that infection before we can see too much about how that impacts vaccine design."
If all goes well, the vaccine will move to phase two, where it will be tested on at-risk people.
© 2024 Newsmax. All rights reserved.